Last reviewed · How we verify
Sigmart (nicorandil)
Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload.
Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload. Used for Angina pectoris (chronic stable angina and angina prophylaxis), Ischemic heart disease.
At a glance
| Generic name | Sigmart (nicorandil) |
|---|---|
| Also known as | Sigmart® |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Potassium channel opener with nitrate-like properties |
| Target | ATP-sensitive potassium channels (KATP) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nicorandil is a potassium channel opener with dual mechanism of action: it activates ATP-sensitive potassium channels in coronary and peripheral blood vessels, causing vasodilation and reducing myocardial oxygen demand. Additionally, it possesses nitrate-like properties that contribute to its vasodilatory effects. This combination reduces both preload and afterload on the heart, improving coronary blood flow and myocardial perfusion.
Approved indications
- Angina pectoris (chronic stable angina and angina prophylaxis)
- Ischemic heart disease
Common side effects
- Headache
- Dizziness
- Palpitations
- Nausea
- Hypotension
Key clinical trials
- Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve (NA)
- Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil (PHASE4)
- Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC (PHASE3)
- Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients (PHASE2)
- Efficacy Study of Nicorandil on Neointima (PHASE4)
- A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization (PHASE4)
- Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sigmart (nicorandil) CI brief — competitive landscape report
- Sigmart (nicorandil) updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI